Brexanolone for postpartum depression: clinical evidence and practical considerations
Abstract
Our aim was to review the efficacy, safety, and pharmacology of brexanolone (Zulresso), a new antidepressant with a novel mechanism of action, in the treatment of postpartum depression ( PPD ). Pertinent data and information were obtained via PubMed (1993 to August 2018). Articles published in English that evaluated the safety and efficacy of brexanolone and other off‐label PPD treatments were included. Literature regarding epidemiology and pathophysiology of PPD was also selected. Brexanolone, administered as an intravenous infusion over 60 hours, produced a statistically significant and clinically meaningful reduction in Hamilton Depression Rating Scale ( HAM ‐D) scores compared with placebo at both 60 and 90 μg/kg/hour in patients with moderate to severe PPD . Brexanolone groups had higher response and remission rates compared with placebo. Common adverse effects were somnolence, dizziness, and headache. A small percentage (4%) of patients required cessation of therapy due to excessive sedation or loss of consciousness. Although the evidence for brexanolone as a novel treatment for PPD looks promising, a Risk Evaluation and Mitigation Strategies ( REMS ) program requirement and the logistics of prolonged infusions serve as barriers to treatment. A discussion of these obstacles as well as pharmacokinetics, monitoring, and dosing is provided. Brexanolone is a novel antidepressant indicated for the treatment of PPD . Clinical trials demonstrated that brexanolone significantly reduces depression scores in women with moderate to severe PPD . Due to risk of oversedation and loss of consciousness, a REMS program will be put in place to mitigate the risk of adverse events.
Integrity signals
Registry
Cites
Statistics
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
There is strong evidence that perinatal mental health conditions can be prevented and effectively treated through psychotherapy and/or pharmacotherapy.
“Importantly, there is strong evidence that PMH conditions can be prevented52-54 and effectively treated through psychotherapy54-57 and/or pharmacotherapy.58,59”
From The transition to parenthood in obstetrics: enhancing prenatal care for 2-generation impact (2022) · cites this paper as [58]
Cites
Risk factors for depressive symptoms during pregnancy: a systematic review
Lancaster, C. A., Gold, K. J., Flynn, H. A., Yoo, H., Marcus, S. M., & Davis, M. M. (2010) · American Journal of Obstetrics and Gynecology · doi:10.1016/j.ajog.2009.09.007 · Cited by 1,208 · see citing works
Meltzer-Brody, S., Colquhoun, H., Riesenberg, R., Epperson, C. N., Deligiannidis, K. M., Rubinow, D. R., Li, H., Sankoh, A. J., Clemson, C., Schacterle, A., et al. (2018) · The Lancet · doi:10.1016/s0140-6736(18)31551-4 · Cited by 795 · see citing works
Transdermal oestrogen for treatment of severe postnatal depression
Grégoire, A., Kumar, R., Everitt, B. J., & Studd, J. W. W. (1996) · The Lancet · doi:10.1016/s0140-6736(96)91414-2 · Cited by 559 · see citing works
Appleby, L., Warner, R., Whitton, A., & Faragher, B. E. (1997) · BMJ · doi:10.1136/bmj.314.7085.932 · Cited by 549 · see citing works
Domestic Violence and Perinatal Mental Disorders: A Systematic Review and Meta-Analysis
Howard, L. M., Oram, S., Galley, H., Trevillion, K., & Feder, G. (2013) · PLoS Medicine · doi:10.1371/journal.pmed.1001452 · Cited by 491 · see citing works
Brexanolone (SAGE-547 injection) in post-partum depression: a randomised controlled trial.
Kanes, S., Colquhoun, H., Gunduz-Bruce, H., Raines, S., Arnold, R., Schacterle, A., Doherty, J., Epperson, C. N., Deligiannidis, K. M., Riesenberg, R., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(17)31264-3 · Cited by 479 · see citing works
Onset and Persistence of Postpartum Depression in an Inner-City Maternal Health Clinic System
Yonkers, K. A., Ramin, S. M., Rush, A. J., Navarrete, C. A., Carmody, T. J., March, D., Heartwell, S., & Leveno, K. J. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.11.1856 · Cited by 358 · see citing works
Trends in postpartum depressive symptoms- 27 States, 2004, 2008, and 2012
Ko, J. Y., Rockhill, K. M., Tong, V. T., Morrow, B., & Farr, S. L. (2017) · MMWR. Morbidity and Mortality Weekly Report · doi:10.15585/mmwr.mm6606a1 · Cited by 334 · see citing works
Sutter‐Dallay, A., Giaconne-Marcesche, V., Glatigny-Dallay, É., & Verdoux, H. (2004) · European Psychiatry · doi:10.1016/j.eurpsy.2004.09.025 · Cited by 273 · see citing works
The STAR*D study: treating depression in the real world.
Gaynes, B. N., Rush, A. J., Trivedi, M. H., Wisniewski, S. R., Spencer, D. D., & D, M. F. M. (2008) · Cleveland Clinic Journal of Medicine · doi:10.3949/ccjm.75.1.57 · Cited by 248 · see citing works
Magiakou, M. A., Mastorakos, G. P., Rabin, D. S., Dubbert, B. K., Gold, P. W., & Chrousos, G. P. (1996) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.81.5.8626857 · Cited by 235 · see citing works
Association between diabetes and perinatal depression among low-income mothers.
Kozhimannil, K., Pereira, M. A., & Harlow, B. (2009) · Journal of the American Medical Association (JAMA) · doi:10.1001/jama.2009.201 · Cited by 227 · see citing works
Räisänen, S., Lehto, S. M., Nielsen, H. S., Gissler, M., Kramer, M. R., & Heinonen, S. T. (2014) · BMJ Open · doi:10.1136/bmjopen-2014-004883 · Cited by 222 · see citing works
The Use of Paroxetine and Cognitive-Behavioral Therapy in Postpartum Depression and Anxiety
Misri, S. K., Reebye, P. N., Corral, M. R., & Milis, L. (2004) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v65n0913 · Cited by 203 · see citing works
Antidepressant treatment for postnatal depression
Molyneaux, E., Howard, L. M., McGeown, H. R., Karia, A. M., & Trevillion, K. (2014) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd002018.pub2 · Cited by 171 · see citing works
Postpartum Depression: A Randomized Trial of Sertraline Versus Nortriptyline
Wisner, K., Hanusa, B., Perel, J., Peindl, K., Piontek, C. M., Sit, D., Findling, R., & Moses-Kolko, E. (2006) · Journal of Clinical Psychopharmacology · doi:10.1097/01.jcp.0000227706.56870.dd · Cited by 168 · see citing works
Pehrson, A. L., & Sánchez, C. (2015) · Drug Design Development and Therapy · doi:10.2147/dddt.s62912 · Cited by 143 · see citing works
Doornbos, B., Dijck-Brouwer, J., Kema, I. P., Tanke, M. A. C., van Goor, S. A., Muskiet, F. A. J., & Korf, J. (2009) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2009.07.013 · Cited by 127 · see citing works
Venlafaxine in the Treatment of Postpartum Depression
Cohen, L. S., Viguera, A. C., Bouffard, S. M., Nonacs, R. M., Morabito, C., Collins, M. H., & Ablon, J. S. (2001) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v62n0803 · Cited by 122 · see citing works
Lefkovics, E., Baji, I., & Rigó, J. (2014) · Infant Mental Health Journal · doi:10.1002/imhj.21450 · Cited by 118 · see citing works
Identification and Management of Peripartum Depression.
Langan, R. C., & Goodbred, A. J. (2016) · PubMed · Cited by 101 · see citing works
Pineles, S., Nillni, Y., Pinna, G., Irvine, J., Webb, A., Hall, K. A. A., Hauger, R., Miller, M. W., Resick, P., Orr, S., et al. (2018) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2018.04.024 · Cited by 99 · see citing works
Yonkers, K. A., Lin, H., Howell, H. B., Heath, A. C., & Cohen, L. S. (2008) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v69n0420 · Cited by 98 · see citing works
Sharp, D., Chew-Graham, C. A., Tylee, A. T., Lewis, G., Howard, L. M., Anderson, I. M., Abel, K. M., Turner, K. M., Hollinghurst, S., Tallon, D., et al. (2010) · Health Technology Assessment · doi:10.3310/hta14430 · Cited by 97 · see citing works
Sertraline in the treatment of women with postpartum major depression
Stowe, Z. N., Casarella, J., Landry, J. C., & Nemeroff, C. B. (1995) · Depression · doi:10.1002/depr.3050030109 · Cited by 94 · see citing works
Milgrom, J., Gemmill, A. W., Ericksen, J., Burrows, G., Buist, A., & Reece, J. (2015) · Australian & New Zealand Journal of Psychiatry · doi:10.1177/0004867414565474 · Cited by 94 · see citing works
A randomized, placebo-controlled, double-blind trial of sertraline for postpartum depression
Hantsoo, L. V., Ward-O’Brien, D., Czarkowski, K. A., Gueorguieva, R. V., Price, L. H., & Epperson, C. N. (2013) · Psychopharmacology · doi:10.1007/s00213-013-3316-1 · Cited by 90 · see citing works
Unintended Pregnancy and Postpartum Depression Among First-Time Mothers
Abbasi, S., Chuang, C. H., Dagher, R. K., Zhu, J., & Kjerulff, K. H. (2013) · Journal of Women s Health · doi:10.1089/jwh.2012.3926 · Cited by 87 · see citing works
Bupropion SR for the treatment of postpartum depression: a pilot study
Nonacs, R. M., Soares, C. N., Viguera, A. C., Pearson, K. H., Poitras, J. R., & Cohen, L. S. (2005) · The International Journal of Neuropsychopharmacology · doi:10.1017/s1461145705005079 · Cited by 82 · see citing works
Fluvoxamine for Postpartum Depression
Suri, R., Burt, V. K., Altshuler, L. L., Zuckerbrow-Miller, J., & Fairbanks, L. A. (2001) · American Journal of Psychiatry · doi:10.1176/appi.ajp.158.10.1739 · Cited by 79 · see citing works
(2013) · American Psychiatric Association Publishing eBooks · doi:10.1176/appi.books.9780890425596.dsm04 · Cited by 70 · see citing works
Platelet serotonin levels support depression scores for women with postpartum depression
Maurer‐Spurej, E., Pittendreigh, C., & Misri, S. K. (2007) · Journal of Psychiatry and Neuroscience · doi:10.1139/jpn.0704 · Cited by 67 · see citing works
Bloch, M., Meiboom, H., Lorberblat, M., Bluvstein, I., Aharonov, I., & Schreiber, S. (2012) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.11m07117 · Cited by 63 · see citing works
Effect of oestradiol on postpartum depression
Ahokas, A., Kaukoranta, J., & Aito, M. (1999) · Psychopharmacology · doi:10.1007/s002130051095 · Cited by 50 · see citing works
O’Hara, M. W., Pearlstein, T. B., Stuart, S. P., Long, J. D., Mills, J. A., & Zlotnick, C. (2018) · Journal of Affective Disorders · doi:10.1016/j.jad.2018.10.361 · Cited by 39 · see citing works
Depressive disorder and thyroid axis functioning during pregnancy
Bunevičius, R., Kusminskas, L., Mickuvienė, N., Bunevičius, A., Pedersen, C. A., & Pop, V. J. M. (2009) · The World Journal of Biological Psychiatry · doi:10.3109/15622970903144038 · Cited by 36 · see citing works
Nefazodone for the treatment of postpartum depression
Suri, R., Burt, V. K., & Altshuler, L. L. (2005) · Archives of Women s Mental Health · doi:10.1007/s00737-005-0071-2 · Cited by 27 · see citing works
Restoration of Functionality in Postpartum Depressed Mothers
Misri, S. K., Abizadeh, J., Albert, G., Carter, D., & Ryan, D. M. (2012) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0b013e31826867c9 · Cited by 26 · see citing works
Fluoxetine treatment of postpartum depression
Roy, A., Cole, K., Goldman, Z., & Barris, M. (1993) · American Journal of Psychiatry · doi:10.1176/ajp.150.8.1273a · Cited by 23 · see citing works
Misri, S. K., Swift, E., Abizadeh, J., & Shankar, R. (2016) · Therapeutic Advances in Psychopharmacology · doi:10.1177/2045125316656297 · Cited by 17 · see citing works
Flagged first, then by citations
1 of the 41 references couldn’t be matched to a known paper.
Cited by
Sorted by citations
Edinoff, A. N., Odisho, A. S., Lewis, K., Kaskas, A. M., Hunt, G., Cornett, E. M., Kaye, A. D., Kaye, A. M., Morgan, J. H., Barrilleaux, P. S., et al. (2021) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.699740 · Cited by 95 · see citing works
Allopregnanolone in mood disorders: Mechanism and therapeutic development
Chen, S., Gao, L., Li, X., & Ye, Y. (2021) · Pharmacological Research · doi:10.1016/j.phrs.2021.105682 · Cited by 69 · see citing works
Allopregnanolone, the Neuromodulator Turned Therapeutic Agent: Thank You, Next?
Pinna, G. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00236 · Cited by 46 · see citing works
Reddy, D. S. (2021) · Journal of Neuroendocrinology · doi:10.1111/jne.13028 · Cited by 46 · see citing works
Reddy, D. S., Mbilinyi, R. H., & Estes, E. (2023) · Psychopharmacology · doi:10.1007/s00213-023-06427-2 · Cited by 37 · see citing works
Zuranolone – synthetic neurosteroid in treatment of mental disorders: narrative review
Marecki, R., Kałuska, J., Kolanek, A., Hakało, D., & Waszkiewicz, N. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1298359 · Cited by 35 · see citing works
Matrisciano, F., & Pinna, G. (2020) · Neurobiology of Stress · doi:10.1016/j.ynstr.2020.100222 · Cited by 35 · see citing works
Xie, H., Xie, Z., Luan, F., Zeng, J., Zhang, X., Chen, L., Zeng, N., & Liu, R. (2024) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2024.117785 · Cited by 27 · see citing works
New agents and perspectives in the pharmacological treatment of major depressive disorder
Sanches, M., Quevedo, J., & Soares, J. C. (2020) · Progress in Neuro-Psychopharmacology and Biological Psychiatry · doi:10.1016/j.pnpbp.2020.110157 · Cited by 25 · see citing works
Gao, Q., Sun, W., Wang, Y.-R., Li, Z., Zhao, F., Geng, X., Xu, K., Chen, D., Liu, K., Xing, Y., et al. (2023) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2023.1140796 · Cited by 23 · see citing works
The Black Book of Psychotropic Dosing and Monitoring
DeBattista, C., & Schatzberg, A. F. (2025) · Psychopharmacology Bulletin · doi:10.64719/pb.4493 · Cited by 22 · see citing works
The transition to parenthood in obstetrics: enhancing prenatal care for 2-generation impact
Monk, C., Dimidjian, S., Galinsky, E., Gregory, K. D., Hoffman, M. C., Howell, E. A., Miller, E. S., Osborne, C., Rogers, C. E., Saxbe, D. E., et al. (2022) · American Journal of Obstetrics & Gynecology MFM · doi:10.1016/j.ajogmf.2022.100678 · Cited by 19 · see citing works
The emergence of antidepressant drugs targeting GABAA receptors: A concise review
Gonda, X., Tarazi, F. I., & Döme, P. (2024) · Biochemical Pharmacology · doi:10.1016/j.bcp.2024.116481 · Cited by 17 · see citing works
Zou, J., Yang, L., Yang, G., & Gao, J. (2023) · Psychiatry Research · doi:10.1016/j.psychres.2023.115450 · Cited by 17 · see citing works
Testosterone Replacement Therapy in the Treatment of Depression
Anderson, D. J., Vazirnia, P., Loehr, C. A., Sternfels, W., Hasoon, J. J., Viswanath, O., Kaye, A. D., & Urits, I. (2022) · Health Psychology Research · doi:10.52965/001c.38956 · Cited by 17 · see citing works
Antidepressant efficacy and side effect burden: an updated guide for clinicians
Kutzer, T., Dick, M., Scudamore, T., Wiener, M., & Schwartz, T. L. (2020) · Drugs in Context · doi:10.7573/dic.2020-2-2 · Cited by 16 · see citing works
Treating Postpartum Depression: What Do We Know about Brexanolone?
Ali, M., Aamir, A., Diwan, M. N., Awan, H. A., Ullah, I., Irfan, M., & Berardis, D. D. (2021) · Diseases · doi:10.3390/diseases9030052 · Cited by 16 · see citing works
Effects of paroxetine treatment and its withdrawal on neurosteroidogenesis
Giatti, S., Diviccaro, S., Cioffi, L., Falvo, E., Caruso, D., & Melcangi, R. C. (2021) · Psychoneuroendocrinology · doi:10.1016/j.psyneuen.2021.105364 · Cited by 15 · see citing works
Niwa, M., Lockhart, S., Wood, D. J., Yang, K., de Oliveira, J. F., Kin, K., Ahmed, A., Wand, G. S., Kano, S., Payne, J. L., et al. (2024) · Nature Mental Health · doi:10.1038/s44220-024-00217-1 · Cited by 14 · see citing works
Research progress of non-monoamine antidepressants
Zhang, H., Wang, B., & Cao, X. (2021) · Stress and Brain · doi:10.26599/sab.2021.9060002 · Cited by 11 · see citing works
Neale, I., Reddy, C. S., Tan, Z. Y., Li, B., Nag, P. P., Park, J., Park, J. J. H. S. J. A. Y., Carey, K. L., Graham, D. B., & Xavier, R. J. (2024) · Science Advances · doi:10.1126/sciadv.adn2339 · Cited by 11 · see citing works
Costa, B., & Vale, N. (2024) · Journal of Clinical Medicine · doi:10.3390/jcm13154398 · Cited by 17 · see citing works
B, G. K., & Roy, S. (2024) · Ain Shams Engineering Journal · doi:10.1016/j.asej.2024.103194 · Cited by 9 · see citing works
Recent Developments in Pharmacotherapy of Depression: Bench to Bedside
Shad, M. U. (2023) · Journal of Personalized Medicine · doi:10.3390/jpm13050773 · Cited by 8 · see citing works
Hamilton depression rating scale: Uses and applications
Renemane, L., & Vrubļevska, J. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-817933-8.00019-0 · Cited by 7 · see citing works
The First Large GWAS Meta-Analysis for Postpartum Depression
Adams, J. A. M., Chandra, P. S., & Mehta, D. (2023) · American Journal of Psychiatry · doi:10.1176/appi.ajp.20230794 · Cited by 6 · see citing works
Bhatti, N. A., Jobilal, A., Asif, K., Villegas, M. J., Pandey, P., Tahir, A. N., Balla, N., Camargo, M. P. A., Ahmad, S., Kataria, J., et al. (2023) · Cureus · doi:10.7759/cureus.44038 · Cited by 6 · see citing works
Medication for Depression: Monoamine Enhancers and Esketamine (Antidepressants)
Park, S., & Shen, W. W. (2023) · Springer eBooks · doi:10.1007/978-3-030-42825-9_133-1 · Cited by 3 · see citing works
Saripalli, A., Amar, P., UCLA/VA Greater Los Angeles, L. A., Duffee, L. E., & Clayton, A. H. (2021) · touchREVIEWS in Neurology · doi:10.17925/usn.2021.17.2.77 · Cited by 2 · see citing works
Neuroactive steroids - new possibilities in the treatment of postpartum depression
Žigová, L., Massarová, P., Vranecová, K., Hrubá, O., Adamičková, A., & Gažová, A. (2022) · Česká a slovenská farmacie · doi:10.5817/csf2022-4-140 · Cited by 2 · see citing works
Niwa, M., Lockhart, S., Wood, D. J., Yang, K., Francis-Oliveira, J., Kin, K., Ahmed, A., Wand, G. S., Kano, S., Payne, J. L., et al. (2021) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.1101/2021.10.13.464258 · Cited by 2 · see citing works
Деева, О. А., Pantileev, A. S., Kravtsova, O. Y., Nikolaev, S. V., Зефиров, Н. А., Povarnina, P. Y., Антипова, Т. А., Гудашева, Т. А., & Дорофеев, В. Л. (2024) · Mendeleev Communications · doi:10.1016/j.mencom.2024.09.018 · Cited by 1 · see citing works
Yao, K., & Liu, H. (2026) · Archives of Women s Mental Health · doi:10.1007/s00737-026-01679-1 · Cited by 1 · see citing works
(2020) · Journal of Obstetric, Gynecologic & Neonatal Nursing · doi:10.1016/j.jogn.2020.08.006
Association of Women’s Health, O. A. N. N. (2020) · Nursing for Women s Health · doi:10.1016/j.nwh.2020.08.003
Hypersomnia due to a medication or substance
Schweitzer, P. K. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-822963-7.00103-1
(2023) · The MIT Press eBooks · doi:10.7551/mitpress/15380.003.0024
O papel da brexanolona no tratamento da depressão pós-parto: uma revisão integrativa
Santos, G. A. C., Lise, A. P. D. A., Machado, H. N., dos Santos, H. M. M., & Cruz, J. R. (2024) · STUDIES IN HEALTH SCIENCES · doi:10.54022/shsv5n2-017
Medications for Depression: Monoamine Enhancers and Esketamine (Antidepressants)
Park, S., & Shen, W. W. (2024) · Springer eBooks · doi:10.1007/978-3-030-51366-5_133
Nuevos fármacos para la depresión posparto
Fontanet, A. A., Salinas, N. E., & Asenjo, J. P. (2025) · FMC - Formación Médica Continuada en Atención Primaria · doi:10.1016/j.fmc.2024.04.008
Meza, M. E., Ramírez-Molina, O., Flores, O. G., Fariña-Oliva, K., Godoy, P. A., Fuentealba, J., & Yévenes, G. E. (2025) · Neural Regeneration Research · doi:10.4103/nrr.nrr-d-24-01194
Yoon, S. (2026) · Clinical and Experimental Obstetrics & Gynecology · doi:10.31083/ceog45609
Xie, G., Weng, H., Yu, J., & Chi, L. (2026) · Medicine · doi:10.1097/md.0000000000049845
- Authors
- Leader, L. D., O'Connell, M., & VandenBerg, A.
- Affiliations
- Michigan Medicine (US)
- Department of Pharmacy Services Michigan Medicine Ann Arbor Michigan
- Corresponding author
- Leader, Lauren D.
- Venue
- Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy
- Publisher
- Wiley
- Published
- 2019-10-07
- Volume
- 39
- Issue
- 11
- Pages
- 1105-1112
- ISSN
- 0277-0008 (ISSN-L)
- 1875-9114
- OpenAlex
- W2972555063
- Cited by
- 43
- References
- 41
- Citations by year
- 2026: 3 · 2025: 3 · 2024: 9 · 2023: 9 · 2022: 3 · 2021: 10 · 2020: 6
- FWCI
- 0.78
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Maternal Mental Health During Pregnancy and Postpartum
- Health Sciences › Medicine › Pharmacology › Treatment of Major Depression
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Pregnancy and Medication Impact
- Keywords
- brexanolone, postpartum depression, antidepressants, intravenous infusion, treatment efficacy and safety, oversedation, loss of consciousness, pharmacokinetics, dosage, adverse effects, maternal mental health
- MeSH terms
- Antidepressive Agents, Drug Combinations, Female, Humans, Pregnancy, Pregnanolone, Psychiatric Status Rating Scales, Severity of Illness Index, GABA Modulators, Depression, Postpartum, beta-Cyclodextrins
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
